TCM patterns and EGFR-TKI response in lung cancer
Part of Cancer clinical trials.
This trial studies how Traditional Chinese Medicine (TCM) patterns relate to the effectiveness of targeted pills (EGFR-TKIs) in lung cancer. It is for people with EGFR-mutated non-small cell lung cancer who are about to start or are already on this type of treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer (the most common type of lung cancer).
- Your tumor must have an EGFR mutation (a specific genetic change).
- You are 18 years or older.
- You are either planning to start an EGFR-targeted pill within 2 weeks, or you are already taking one.
- You are in good enough health to do daily activities with little or no help.
- You are not pregnant or breastfeeding, and you do not have other serious uncontrolled cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks back at how people with non-small cell lung cancer (NSCLC) were treated with EGFR-targeted medicines (gefitinib, erlotinib, and osimertinib). It may help doctors understand which patients benefit most and what side effects to expect.
This study looks at how well patients with early-stage lung cancer (that has been surgically removed) do when treated with a targeted drug called EGFR-TKI to prevent cancer from coming back. Researchers will track actual patient outcomes in China from 2023 to 2026.
This trial tests whether a targeted therapy pill (EGFR-TKI) can control small spots in the other lung after surgery for early-stage lung cancer. It's for people whose cancer has a specific EGFR gene change and who still have suspicious spots in the opposite lung after one side is removed.
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
This study tests three different targeted pills (osimertinib, afatinib, dacomitinib) in people with advanced EGFR-mutated lung cancer who haven't had targeted therapy before. The goal is to find which pill works best and has the fewest side effects.
Hear when a new Non Small Cell Lung Cancer NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.